Does Vitamin E Work? What the Big Trials Actually Found
Educational summary — not medical advice. This page describes what randomized trials found; it isn't a recommendation to take or stop anything. Talk to your clinician before any supplement, especially with blood thinners. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
The honest answer
For the reasons people buy it, no — and possibly worse. The largest independent trials found no heart-disease or cancer prevention from vitamin E, plus harm signals at 400 IU: increased prostate cancer (SELECT, HR 1.17; Klein 2011), a heart-failure signal (HOPE-TOO, RR 1.13; Lonn 2005), and higher all-cause mortality at ≥400 IU (Miller 2005 — mostly in chronically-ill people). The one genuine niche is biopsy-proven NASH at 800 IU in non-diabetics (PIVENS, Sanyal 2010) — and even there it didn't improve fibrosis.
Why people expected it to work — and why that theory failed
Vitamin E is a fat-soluble antioxidant, and for decades the hope was that mopping up oxidative damage would prevent heart disease and cancer. Observational studies that linked higher vitamin E intake to better outcomes fueled that story. But when it was tested the right way — large randomized controlled trials, the design that separates cause from coincidence — the benefit vanished, and in places the needle moved the wrong way. This is the classic "antioxidant supplement" disappointment: what looked promising in test tubes and correlations did not hold up when high-dose vitamin E was given to real people and compared against placebo.
What the trials show — read them together
These are the largest and most cited randomized trials and the pooled meta-analysis. Note the doses: HOPE, SELECT, and much of the Miller analysis center on the same 400 IU most supplements sell.
| Trial | Who & dose | Finding | The honest read |
|---|---|---|---|
| HOPE 2000 (NEJM) PMID 10639540 | High-risk adults (CVD or diabetes), 400 IU/day | No reduction in cardiovascular events (RR ~1.05) | The flagship CV-prevention test was flatly null at the standard retail dose |
| HOPE-TOO 2005 (JAMA) PMID 15769967 | HOPE patients, extended to ~7 years, 400 IU/day | No cancer or CV benefit; heart failure RR 1.13 (95% CI 1.01–1.26) | Longer follow-up didn't rescue it — and surfaced a heart-failure signal |
| SELECT 2011 (JAMA) PMID 21990298 | Healthy men, 400 IU/day | Increased prostate cancer, HR 1.17 (99% CI 1.004–1.36) | Not just "no benefit" — a statistically significant increase in a cancer |
| Miller meta-analysis 2005 (Ann Intern Med) PMID 15537682 | 19 RCTs pooled; dose-response around ≥400 IU/day | Increased all-cause mortality at ≥400 IU/day (~+39 deaths/10,000) | Caveat: mostly older, chronically-ill trial populations — not a precise risk for a healthy adult |
| PIVENS 2010 (NEJM) PMID 20427778 | Non-diabetic adults, biopsy-proven NASH, 800 IU/day | Improved NASH histology 43% vs 19% placebo; fibrosis not improved | The one real positive — but narrow, biopsy-confirmed, and fibrosis unchanged |
Reading the mortality number responsibly The Miller meta-analysis found higher all-cause mortality at ≥400 IU/day, but the trials it pooled were largely in older people with existing chronic disease. So the "+39 deaths per 10,000" figure should be read as a caution flag against high-dose supplementation, not a precise mortality risk for a healthy young adult. Later meta-analyses have debated the exact size and shape of the effect. The safe conclusion isn't "vitamin E kills you"; it's "high-dose vitamin E has no demonstrated benefit and a credible harm signal — so there's no good reason to take 400 IU."
So who, if anyone, is it reasonable for?
- Most people: no supplement needed. Food meets the ~22 IU RDA, and the high-dose trials show no benefit for heart or cancer prevention — the usual reasons people buy it.
- People with a diagnosed fat-malabsorption condition (e.g. cystic fibrosis, cholestatic liver disease) can develop true deficiency and may need supplementation — but that's replacement to normal, managed by a clinician, not high-dose antioxidant dosing.
- Biopsy-proven NASH in non-diabetics is the one place a specialist might use 800 IU (PIVENS) — again, a managed medical decision, not self-care.
- Don't take 400 IU to prevent heart disease or cancer. That's the exact use the trials tested and it failed, with harm signals attached.
Frequently asked questions
Does vitamin E prevent heart disease?
No. HOPE found no CV benefit at 400 IU, and HOPE-TOO found none over ~7 years plus a heart-failure signal (RR 1.13). It's not heart-protective.
Does vitamin E prevent cancer?
No — and SELECT found 400 IU/day increased prostate cancer in healthy men (HR 1.17). HOPE-TOO found no cancer prevention. Don't take it to lower cancer risk.
Is high-dose vitamin E dangerous?
There are real signals: higher all-cause mortality at ≥400 IU in a 19-trial meta-analysis (mostly chronically-ill populations), plus the prostate-cancer and heart-failure findings and a blood-thinning effect. No benefit, several cautions.
Is it good for fatty liver?
Only narrowly: 800 IU improved NASH histology in non-diabetics with a liver biopsy (PIVENS, 43% vs 19%) but not fibrosis. That's clinician-managed for a specific diagnosis — not "treats fatty liver" broadly, and not for self-dosing.
Related
- Vitamin E: what it is & who it's for
- Vitamin E dosage guide — RDA ~22 IU vs the 400 IU harm threshold, plus a checker
- Natural vs synthetic & dose — the label facts that matter
- Best vitamin E — ranked by form, flagging the high-dose alpha
Sources
- Yusuf S, et al. (HOPE Study Investigators). "Vitamin E supplementation and cardiovascular events in high-risk patients." N Engl J Med. 2000. PMID: 10639540
- Lonn E, et al. "Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial (HOPE-TOO)." JAMA. 2005. PMID: 15769967
- Klein EA, et al. "Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)." JAMA. 2011. PMID: 21990298
- Miller ER 3rd, et al. "Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality." Ann Intern Med. 2005. PMID: 15537682
- Sanyal AJ, et al. "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis (PIVENS)." N Engl J Med. 2010. PMID: 20427778
- NIH Office of Dietary Supplements, Vitamin E Fact Sheet (RDA ~22 IU natural; upper limit and bleeding-risk context). Non-PMID reference.